Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only the grapefruit–CYP3A4/↑atorvastatin exposure concept is supported by the provided label text. Multiple other claims introduce food-specific protein/supplement interaction assertions, specific dosing-timing (“any time”), and diet–LDL effects that are not supported by the supplied prescribing information.
Category Scores
Accurate Statements
Grapefruit is known to raise atorvastatin drug levels by inhibiting the CYP3A4 enzyme that clears the medication.
Supported by label sections 7.2 Grapefruit Juice and 12.3 Pharmacokinetics (Table 3) indicating grapefruit juice components inhibit CYP3A4 and increase plasma concentrations, especially with excessive intake.
Unsupported Statements
Protein intake does not change how Lipitor (atorvastatin) works.
Not supported in the provided label text; no protein-specific or high/low protein effect is stated.
Atorvastatin blocks an enzyme in the liver involved in making cholesterol.
The provided label excerpts do not state this mechanism in that specific manner.
Atorvastatin’s action occurs whether protein intake is high or low.
Not supported by the provided label excerpts.
Chicken does not alter atorvastatin absorption or metabolism.
Not addressed in provided label excerpts.
Fish does not alter atorvastatin absorption or metabolism.
Not addressed in provided label excerpts.
Eggs do not alter atorvastatin absorption or metabolism.
Not addressed in provided label excerpts.
Beans do not alter atorvastatin absorption or metabolism.
Not addressed in provided label excerpts.
Seville oranges are known to raise atorvastatin drug levels by inhibiting the CYP3A4 enzyme that clears the medication.
Label support provided concerns grapefruit juice; Seville oranges are not supported in the supplied label excerpts.
Very high saturated fat and cholesterol diets can blunt the LDL drop produced by Lipitor.
Not supported by the supplied label excerpts; diet counseling is mentioned generally without this specific claim.
Choosing lean protein sources keeps saturated-fat intake low.
Not supported by the supplied label excerpts.
Keeping saturated-fat intake low supports the statin’s effect (LDL reduction).
Not supported by the supplied label excerpts.
Whey protein has no documented pharmacokinetic interaction with atorvastatin.
The provided label excerpts do not provide whey-protein interaction information; stating 'no interaction' goes beyond label content.
Whey can be taken at any time with atorvastatin.
No supplement-specific timing guidance is provided in the supplied label excerpts.
Casein protein has no documented pharmacokinetic interaction with atorvastatin.
No casein-protein interaction information is provided in the supplied label excerpts; 'no interaction' is not label-supported.
Casein can be taken at any time with atorvastatin.
No supplement-specific timing guidance is provided in the supplied label excerpts.
Soy powder has no documented pharmacokinetic interaction with atorvastatin.
No soy-protein interaction information is provided in the supplied label excerpts; 'no interaction' is not label-supported.
Soy powder can be taken at any time with atorvastatin.
No supplement-specific timing guidance is provided in the supplied label excerpts.
Whey, casein, or soy powders can be taken at any time provided the overall diet stays within recommended saturated-fat limits.
Not supported by the supplied label excerpts (no supplement-specific 'any time' claim and no stated 'recommended saturated-fat limits' tied to these foods).
Guidelines recommend replacing saturated-fat calories with lean protein to lower LDL further in Lipitor users.
Not supported in the provided label excerpts; only general reference to NCEP guidelines is present without this specific recommendation.
Guidelines state that lean protein replacement protects heart health in Lipitor users.
Not supported in the provided label excerpts.
Protein helps maintain muscle mass.
Not supported in the provided label excerpts.
Maintaining muscle mass supports physical activity that complements statin therapy.
Not supported in the provided label excerpts.
Pfizer’s original Lipitor (atorvastatin) patent expired in 2011.
Not supported in the provided label excerpts (label does not cover patent status).
Multiple manufacturers now supply generic atorvastatin.
Not supported in the provided label excerpts (label does not cover generic manufacturer supply).
Contradictions
Important Omissions
No label-supported statements about protein/specific foods are provided; however, an accurate alignment would have avoided supplement/food-specific interaction and timing claims that are absent from the label.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The only clearly label-supported interaction is grapefruit juice. Several unsupported claims assert 'no interaction' and 'any time' timing for protein powders and assert diet effects on LDL, which could mislead readers by presenting unlabeled interaction/timing guidance as if it were established by the prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Multiple food/supplement-specific pharmacokinetic and timing assertions are not supported by the provided FDA label excerpts; grapefruit is the only interaction claim supported.
Suggested Improvement
Remove or revise all protein/food-specific and 'any time' supplement-timing claims that are not explicitly supported in the provided label text. Keep only grapefruit juice interaction statements and general, label-referenced guidance (e.g., that food may affect absorption rate/extent but LDL-C reduction is similar with or without food, as stated).